Published in Int Immunopharmacol on December 01, 2002
Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol (2009) 1.70
Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol (2004) 1.17
Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors. Neuropeptides (2010) 1.15
Kinin B1 receptor enhances the oxidative stress in a rat model of insulin resistance: outcome in hypertension, allodynia and metabolic complications. PLoS One (2010) 0.96
Cognitive and cerebrovascular improvements following kinin B1 receptor blockade in Alzheimer's disease mice. J Neuroinflammation (2013) 0.91
Wortmannin alters the intracellular trafficking of the bradykinin B2 receptor: role of phosphoinositide 3-kinase and Rab5. Biochem J (2003) 0.91
Cytokines and neutrophils as important mediators of platelet-activating factor-induced kinin B1 receptor expression. Br J Pharmacol (2005) 0.85
Bradykinin shifts endothelial fluid passage from para- to transcellular routes. Pflugers Arch (2006) 0.84
Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors. Pharmacol Res Perspect (2015) 0.83
Effects of inactivation-resistant agonists on the signalling, desensitization and down-regulation of bradykinin B(2) receptors. Br J Pharmacol (2009) 0.81
Bradykinin does not induce gap formation between human endothelial cells. Pflugers Arch (2007) 0.80
Antagonist, partial agonist and antiproliferative actions of B-9870 (CU201) as a function of the expression and density of the bradykinin B1 and B2 receptors. Br J Pharmacol (2006) 0.78
Comparative proteomics of cerebrospinal fluid reveals a predictive model for differential diagnosis of pneumococcal, meningococcal, and enteroviral meningitis, and novel putative therapeutic targets. BMC Genomics (2015) 0.75
Functional normalization of 450k methylation array data improves replication in large cancer studies. Genome Biol (2014) 2.37
Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension (2007) 1.93
Cellular dissection of circadian peptide signals with genetically encoded membrane-tethered ligands. Curr Biol (2009) 1.90
The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci (2005) 1.87
Tissue kallikrein actions at the rabbit natural or recombinant kinin B2 receptors. Hypertension (2003) 1.56
Generation of kinins during preparation and storage of whole blood-derived platelet concentrates. Transfusion (2007) 1.49
A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet (2005) 1.29
Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet (2002) 1.22
Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des (2003) 1.14
Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am (2006) 1.12
Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther (2002) 1.12
Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach. Stroke (2002) 1.11
Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation (2002) 1.11
Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. Br J Pharmacol (2004) 1.08
Biocompatibility of thermosensitive chitosan-based hydrogels: an in vivo experimental approach to injectable biomaterials. Biomaterials (2002) 0.98
Improved post-myocardial infarction survival with probucol in rats: effects on left ventricular function, morphology, cardiac oxidative stress and cytokine expression. J Am Coll Cardiol (2002) 0.95
MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment. Mol Vis (2005) 0.94
Modulation of inflammation by kininogen deficiency in a rat model of inflammatory arthritis. Arthritis Rheum (2005) 0.94
Derivatized 2-furoyl-LIGRLO-amide, a versatile and selective probe for proteinase-activated receptor 2: binding and visualization. J Pharmacol Exp Ther (2008) 0.92
Ultra-small gadolinium oxide nanoparticles to image brain cancer cells in vivo with MRI. Contrast Media Mol Imaging (2010) 0.91
Four missense mutations in the ghrelin receptor result in distinct pharmacological abnormalities. J Pharmacol Exp Ther (2007) 0.90
Lack of direct interaction between enalaprilat and the kinin B1 receptors. Peptides (2007) 0.90
Vasopeptidase inhibitors: a new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics. Curr Opin Pharmacol (2002) 0.89
Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol (2007) 0.88
Kininogen deficiency modulates chronic intestinal inflammation in genetically susceptible rats. Am J Physiol Gastrointest Liver Physiol (2002) 0.88
Human recombinant membrane-bound aminopeptidase P: production of a soluble form and characterization using novel, internally quenched fluorescent substrates. Biochem J (2005) 0.87
A ligand-based approach to investigate the expression and function of angiotensin converting enzyme in intact human umbilical vein endothelial cells. Peptides (2010) 0.86
Covalent grafting of fibronectin onto plasma-treated PTFE: influence of the conjugation strategy on fibronectin biological activity. Macromol Biosci (2007) 0.86
Demonstration of the innate electrophilicity of 4-(3-(benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP), a small-molecule positive allosteric modulator of the glucagon-like peptide-1 receptor. Drug Metab Dispos (2013) 0.86
Vascular smooth muscle contractility assays for inflammatory and immunological mediators. Int Immunopharmacol (2010) 0.85
Microtubule-destabilizing agents induce focal adhesion structure disorganization and anoikis in cancer cells. J Pharmacol Exp Ther (2006) 0.85
On the ability of imatinib mesylate to inhibit smooth muscle cell proliferation without delaying endothelialization: an in vitro study. Vascul Pharmacol (2009) 0.85
Design, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4. J Med Chem (2011) 0.85
Structural modification of the highly potent peptide bradykinin B1 receptor antagonist B9958. Int Immunopharmacol (2007) 0.85
Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin. Int J Oncol (2005) 0.83
Insulin modulates protease-activated receptor 2 signaling: implications for the innate immune response. J Immunol (2010) 0.82
A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis. Am J Pathol (2004) 0.82
Membrane tethered bursicon constructs as heterodimeric modulators of the Drosophila G protein-coupled receptor rickets. Mol Pharmacol (2013) 0.82
Engineering surfaces for bioconjugation: developing strategies and quantifying the extent of the reactions. Bioconjug Chem (2004) 0.82
Role of nuclear factor-kappaB and protein kinase C signaling in the expression of the kinin B1 receptor in human vascular smooth muscle cells. Mol Pharmacol (2006) 0.82
A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema. Hum Mutat (2011) 0.81
Comparative effects of a vasopeptidase inhibitor vs. an angiotensin converting enzyme inhibitor on cardiomyocyte apoptosis in rats with heart failure. Mol Cell Biochem (2003) 0.81
Inhibition of human and rabbit arterial smooth muscle cell migration mediated by the kinin B1 receptor: role of receptor density and released mediators. Can J Physiol Pharmacol (2006) 0.81
Novel inactivating mutations in the GH secretagogue receptor gene in patients with constitutional delay of growth and puberty. Eur J Endocrinol (2011) 0.81
Optimized N-phenyl-N'-(2-chloroethyl)ureas as potential antineoplastic agents: synthesis and growth inhibition activity. Bioorg Med Chem (2005) 0.81
Do angiotensin-converting enzyme inhibitors directly stimulate the kinin B1 receptor? Am J Physiol Heart Circ Physiol (2003) 0.81
Effects of inactivation-resistant agonists on the signalling, desensitization and down-regulation of bradykinin B(2) receptors. Br J Pharmacol (2009) 0.81
Fluorescent ligands of the bradykinin B1 receptors: pharmacologic characterization and application to the study of agonist-induced receptor translocation and cell surface receptor expression. J Pharmacol Exp Ther (2009) 0.81
New soft alkylating agents with enhanced cytotoxicity against cancer cells resistant to chemotherapeutics and hypoxia. Cancer Res (2007) 0.81
Studies on rabbit natural and recombinant tissue factors: intracellular retention and regulation of surface expression in cultured cells. Am J Physiol Heart Circ Physiol (2005) 0.81
A novel nonpeptide antagonist of the kinin B1 receptor: effects at the rabbit receptor. J Pharmacol Exp Ther (2004) 0.80
Effect of interferon-γ on inflammatory cytokine-induced bradykinin B1 receptor expression in human vascular cells. Eur J Pharmacol (2010) 0.80
Hypotensive reaction during staphylococcal protein A column therapy in a patient with anomalous degradation of bradykinin and Des-Arg9-bradykinin after contact activation. Transfusion (2002) 0.80
Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage. Transfusion (2004) 0.80
Proteinases as hormone-like signal messengers. Swiss Med Wkly (2005) 0.80
Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat. J Am Coll Cardiol (2002) 0.80
Alkylation potency and protein specificity of aromatic urea derivatives and bioisosteres as potential irreversible antagonists of the colchicine-binding site. Bioorg Med Chem (2007) 0.79
The syndrome of amniotic fluid embolism: a potential contribution of bradykinin. Am J Obstet Gynecol (2005) 0.79
The effect of electronegativity and angiotensin-converting enzyme inhibition on the kinin-forming capacity of polyacrylonitrile dialysis membranes. Biomaterials (2008) 0.79
Substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides as antimitotics. Antiproliferative, antiangiogenic and antitumoral activity, and quantitative structure-activity relationships. Eur J Med Chem (2011) 0.79
Effects of captopril and omapatrilat on early post-myocardial infarction survival and cardiac hemodynamics in rats: interaction with cardiac cytokine expression. Can J Physiol Pharmacol (2002) 0.79
Kinin B1 receptors contributes to acute pain following minor surgery in humans. Mol Pain (2010) 0.79
A fluorescent version of the bradykinin B2 receptor antagonist B-9430: pharmacological characterization and use in live cell imaging. Peptides (2008) 0.79
ASK1-P38 pathway is important for anoikis induced by microtubule-targeting aryl chloroethylureas. J Pharm Pharm Sci (2010) 0.79
Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents. Bioorg Med Chem (2008) 0.78
Aromatic 2-chloroethyl urea derivatives and bioisosteres. Part 2: Cytocidal activity and effects on the nuclear translocation of thioredoxin-1, and the cell cycle progression. Bioorg Med Chem (2008) 0.78
Loss of function of vascular smooth muscle cells by nitric oxide-dependent and -independent interactions with tumorigenic cells. Int J Cancer (2004) 0.78
Synthesis, antiproliferative activity evaluation and structure-activity relationships of novel aromatic urea and amide analogues of N-phenyl-N'-(2-chloroethyl)ureas. Eur J Med Chem (2010) 0.78
Mechanism of action of N-phenyl-N'-(2-chloroethyl)ureas in the colchicine-binding site at the interface between alpha- and beta-tubulin. Bioorg Med Chem (2009) 0.78
Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation. Bioorg Med Chem Lett (2008) 0.78
Met-Lys-bradykinin-Ser-Ser, a peptide produced by the neutrophil from kininogen, is metabolically activated by angiotensin converting enzyme in vascular tissue. Pharmacol Res (2011) 0.78
Quick and simple detection technique to assess the binding of antimicrotubule agents to the colchicine-binding site. Biol Proced Online (2010) 0.78
A study of the mediators involved in the protection induced by exogenous kinins in the isolated rat heart. Int Immunopharmacol (2003) 0.78
Expression of metallopeptidases and kinin receptors in swine oropharyngeal tissues: effects of angiotensin I-converting enzyme inhibition and inflammation. J Pharmacol Exp Ther (2005) 0.78
Tumor cells expressing tissue factor influence the migration of smooth muscle cells in a catalytic activity-dependent way. Can J Physiol Pharmacol (2009) 0.77
Effect of reproductive hormones on ovarian epithelial tumors: II. Effect on angiogenic activity. Cancer Biol Ther (2002) 0.77
Chronic intestinal inflammation and angiogenesis in genetically susceptible rats is modulated by kininogen deficiency. Int Immunopharmacol (2002) 0.77
Cardiovascular expression of inflammatory signaling molecules, the kinin B1 receptor and COX2, in the rabbit: effects of LPS, anti-inflammatory and anti-hypertensive drugs. Regul Pept (2007) 0.77
Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol (2002) 0.77
Characterization of currently marketed heparin products: adverse event relevant bioassays. J Pharm Biomed Anal (2012) 0.77
Chloroethyl urea derivatives block tumour growth and thioredoxin-1 nuclear translocation. Can J Physiol Pharmacol (2010) 0.76
Endogenous aminopeptidase N decreases the potency of peptide agonists and antagonists of the kinin B1 receptors in the rabbit aorta. J Pharmacol Exp Ther (2005) 0.76
Two naturally occurring mutations in the type 1 melanin-concentrating hormone receptor abolish agonist-induced signaling. J Pharmacol Exp Ther (2010) 0.76
Latest approaches for the treatment of obesity. Expert Opin Drug Discov (2015) 0.76
Long-term effects of carvedilol on left ventricular function, remodeling, and expression of cardiac cytokines after large myocardial infarction in the rat. J Cardiovasc Pharmacol (2002) 0.75
Discovery of a dual-function peptide that combines aminopeptidase N inhibition and kinin B1 receptor antagonism. J Pharmacol Exp Ther (2005) 0.75
Receptor tyrosine kinases as mediators of injury-induced bradykinin B1 receptor expression in rabbit aortic smooth muscle. Eur J Pharmacol (2009) 0.75
Acute hypotensive transfusion reaction during liver transplantation in a patient on angiotensin converting enzyme inhibitors from low aminopeptidase P activity. Liver Transpl (2008) 0.75